EIKN Eikon Therapeutics (EIKN) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001861123
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
55
13F, latest reported quarter
What the filings say about EIKN
Insiders, 180 days
+$1.0M net bought
1 buyer
Eikon Therapeutics insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Eikon Therapeutics, Inc. insiders bought a net $1.0M of stock across 8 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 89,200 shares held after it.
- No other insider bought within 30 days.
- 55 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Column Group IV GP, LP bought about $1.0M of EIKN on Sep 3, 2026; 55 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 47.8% of the 1,319,164 shares held after it.
- 4 other insiders bought within 30 days.
- 55 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Column Group Opportunity III, LP bought about $11.4M of EIKN on Feb 6, 2026, the largest insider purchase at the company on our record; 4 other insiders bought within 30 days and 55 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 33.3% of the 148,840 shares held after it.
- 4 other insiders bought within 30 days.
- 55 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Column Group Opportunity III, LP bought about $892.0K of EIKN on Feb 6, 2026; 4 other insiders bought within 30 days and 55 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 33.3% of the 4,312,139 shares held after it.
- 4 other insiders bought within 30 days.
- 55 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Column Group Opportunity III, LP bought about $25.9M of EIKN on Feb 6, 2026, the largest insider purchase at the company on our record; 4 other insiders bought within 30 days and 55 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 4.2% of the 1,318,983 shares held after it.
- 4 other insiders bought within 30 days.
- 55 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Foresite Capital Opportunity Management V, LLC bought about $1,000.0K of EIKN on Feb 4, 2026, the largest insider purchase at the company on our record; 4 other insiders bought within 30 days and 55 funds added in the latest 13F quarter.8 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$1.0M over 180 days
+$1.0M over 90 days · +$1.0M of it by a 10%+ holder
more than 88% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
55 funds bought in last quarter
below 51% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
18.3% of the float short (float per yahoo 2026-10-27) · 11.7 days to cover · settled 2026-10-15
more than 78% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch EIKN
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-63.1%12M
Insider buyInsider sell13D/G stake
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns EIKN: institutional holders (13F)
13F holdings, latest reported quarter
4,993,906 sh
$65.2M
4,281,425 sh
$55.9M
1,943,682 sh
$25.4M
1,666,666 sh
$21.7M
1,318,983 sh
$17.2M
Congress trades in EIKN
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
The Column Group IV GP, LP
Activist 13D · 2026-02-12
8.3%
The Column Group IV, LP
Activist 13D · 2026-02-12
8.0%
The Column Group IV-A, LP
Activist 13D · 2026-02-12
0.3%
The Column Group Opportunity III, LP
Activist 13D · 2026-02-12
3.5%
The Column Group Opportunity III GP, LP
Activist 13D · 2026-02-12
3.5%
EIKN planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
EIKN mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
T. Rowe Price Health Care ETF
$72.1K position · as of 2026-06-30
0.3%
Select Biotechnology Portfolio
$10.6M position · as of 2026-05-31
0.2%
AB Small Cap Growth Portfolio
$114.0K position · as of 2026-06-30
0.2%
Health Sciences Portfolio
$562.5K position · as of 2026-06-30
0.1%
BlackRock Health Sciences Opportunities Portfolio
$7.8M position · as of 2026-05-29
0.1%
T. Rowe Price Small-Cap Value Fund, Inc.
$12.1M position · as of 2026-06-30
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
10 registered trials, 6 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
3
Phase 1
0 active
2
Phase 2
1 active
5
Multi-phase
5 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $1.0M bought by insiders over 180 days, 55 funds added last quarter. Each figure is a federal filing, dated the day it went public.
EIKN Stock Sonar score 3/7 axes
Find similar shapesCompareEIKN ranks highest on insider conviction (72nd percentile) and institutional and government (49th), and lowest on risk and compliance (18th), among Pharma & Biotech peers.
3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
EIKN filings, in plain words
Are Eikon Therapeutics insiders buying or selling EIKN?
In the 180 days to 2026-10-28, Eikon Therapeutics insiders were net buyers, a net $1.0M across purchases and sales reported on Form 4, by 1 buyer.
Read the full summary
In the 180 days to 2026-10-28, Eikon Therapeutics insiders were net buyers of EIKN, a net $1.0M across purchases and sales reported on Form 4 by 1 buyer. Most of that figure, $1.0M, came from a holder of 10% or more rather than an officer or director. The latest 5% ownership filing is a 13D by The Column Group IV GP, LP, filed 2026-02-12, for 8.3% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
